Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Currently Amended) A compound of formula (I) ~~or a pharmaceutically acceptable salt thereof~~:



(I)

wherein:

R^1 represents aryl, heteroaryl,-aryl-X-aryl, -aryl-X-heteroaryl, -aryl-X-heterocyclyl, -heteroaryl-X-heteroaryl, -heteroaryl-X-aryl or –heteroaryl-X-heterocyclyl;

wherein said aryl, heteroaryl and heterocyclyl groups of R^1 may be optionally substituted by one or more ~~(e.g. 1, 2 or 3)~~ substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, oxo, haloC_{1-6} alkyl, polyhaloC_{1-6} alkyl, haloC_{1-6} alkoxy, polyhaloC_{1-6} alkoxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxyC_{1-6} alkyl, C_{3-7} cycloalkylC_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkoxycarbonyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylsulfonylC_{1-6} alkyl, C_{1-6} alkylsulfonamidoC_{1-6} alkyl, C_{1-6} alkylamidoC_{1-6} alkyl, aryl, arylsulfonyl, arylsulfonyloxy, aryloxy, arylsulfonamido, arylcarboxamido, aroyl, ~~or a group~~ –COR^{15}, -$COOR^{15}$, $NR^{15}R^{16}$, -$CONR^{15}R^{16}$, -$NR^{15}COR^{16}$, -$NR^{15}SO_2R^{16}$, and ~~or~~ -$SO_2NR^{15}R^{16}$, wherein R^{15} and R^{16} independently represent hydrogen, C_{1-6} alkyl, haloC_{1-6} alkyl, polyhaloC_{1-6} alkyl, or C_{3-6} cycloalkyl, or R^{15} and R^{16} together form a heterocyclic ring;

X represents a bond, O, CO, SO_2, OCH_2 or CH_2O;

R^2 represents C_{3-8} alkyl, C_{3-6} alkenyl, C_{3-6} alkynyl, C_{3-6} cycloalkyl, C_{5-6} cycloalkenyl, or -C_{1-4}alkyl-C_{3-6} cycloalkyl;

wherein said C_{3-6} cycloalkyl groups of R^2 may be optionally substituted by one or more ~~(e.g. 1, 2 or 3)~~ substituents which may be the same or different, and which are selected from the group consisting of halogen, C_{1-4} alkyl, and ~~or~~ trifluoromethyl groups;

each R^3 and R^4 group independently represents C_{1-4} alkyl;

m and n independently represent~~s~~ 0, 1 or 2;

p and q independently represent~~s~~ 1 or 2;

or a pharmaceutically acceptable salt thereof.

2. (Currently Amended) ~~A~~ The compound of formula (I) as defined in claim 1 wherein R^1 represents

-aryl optionally substituted by a cyano, $-CONR^{15}R^{16}$, $-COR^{15}$, halogen, or $-NR^{15}COR^{16}$ group;

-heteroaryl optionally substituted by a cyano, C_{1-6} alkyl, polyhaloC_{1-6} alkyl, $-CONR^{15}R^{16}$, $-COR^{15}$, or $-COOR^{15}$ group;

-aryl-X-heterocyclyl;

-aryl-X-heteroaryl optionally substituted by a halogen, C_{1-6} alkyl, or aryl group; or

-heteroaryl-X-heterocyclyl.

3. (Currently Amended) ~~A~~ The compound of formula (I) as defined in claim 2 wherein R^1 represents

pyrid-3-yl optionally substituted by a $-CONR^{15}R^{16}$ group,

–phenyl-1,2,4-oxadiazol-5-yl optionally substituted by a C_{1-6} alkyl group,

phenyl optionally substituted by a $-COR^{15}$ group,

pyridazin-3-yl optionally substituted by a polyhaloC_{1-6} alkyl group,

pyrazin-2-yl optionally substituted by a polyhaloC_{1-6} alkyl, or

pyrimidin-5-yl optionally substituted by a polyhaloC_{1-6} alkyl group.

4. (Currently Amended) ~~A~~ The compound of formula (I) as defined in claim 3 wherein R^1 represents

pyrid-3-yl optionally substituted by a 6–CON(H)(Me) or 6–CON(H)(Et) group,

3-methyl-1,2,4-oxadiazol-5-yl, phenyl optionally substituted by a 4–COMe group,

pyridazin-3-yl optionally substituted by a 6–CF_3 group, or

pyrimidin-5-yl optionally substituted by a 2–CF_3 group.

5. (Currently Amended) ~~A~~ The compound of formula (I) as defined in ~~any one of claims 1 to 4~~ claim 1 wherein m and n represent 0.

6. (Currently Amended) ~~A~~ The compound of formula (I) as defined in ~~any one of claims 1 to 5~~ claim 1 wherein p and q represent 1.

7. (Currently Amended) ~~A~~ The compound of formula (I) as defined in ~~any one of claims 1 to 6~~ claim 1 wherein R^2 represents C_{3-8} alkyl, C_{3-6} cycloalkyl, or -C_{1-4}alkyl-C_{3-6} cycloalkyl.

8. (Currently Amended) ~~A~~ The compound of formula (I) as defined in claim 7 wherein R^2 represents 1-methylpropyl, isopropyl, cyclobutyl, or $–CH_2$-cyclopropyl.

9. (Currently Amended) ~~A~~ The compound of formula (I) as defined in claim 8 wherein R^2 represents isopropyl or cyclobutyl.

10. (Currently Amended) ~~A~~ The compound as defined in claim 1 which is a compound of formula E1-E120 or a pharmaceutically acceptable salt thereof.

11. (Currently Amended) ~~A~~ The compound as defined in claim 1 which is
1-(1-methylethyl)-4-({1-[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-4-piperidinyl}oxy)piperidine;
5-{4-[(1-cyclobutyl-4-piperidinyl)oxy]-1-piperidinyl}-*N*-methyl-2-pyridinecarboxamide;
1-(4-{4-[(1-cyclobutyl-4-piperidinyl)oxy]-1-piperidinyl}phenyl)ethanone;
3-{4-[(1-cyclobutyl-4-piperidinyl)oxy]-1-piperidinyl}-6-(trifluoromethyl)pyridazine;
or
5-{4-[(1-cyclobutyl-4-piperidinyl)oxy]-1-piperidinyl}-2-(trifluoromethyl)pyrimidine;
or a pharmaceutically acceptable salt thereof.

12. (Currently Amended) A pharmaceutical composition which comprises the compound of formula (I) as defined in ~~any one of claims 1 to 11~~ claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

13. – 15. (Cancelled).

16. (Currently Amended) A method of treatment of neurological diseases which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in ~~any one of claims 1 to 11~~ claim 1 or a pharmaceutically acceptable salt thereof.

17. (Cancelled).

18. (Original) A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:

(a) reacting a compound of formula (II)



(II)

wherein R^2, R^3, R^4, m, n, p and q are as defined in claim 1, with a compound of formula R^1-L^1, wherein R^1 is as defined in claim 1 and L^1 represents a suitable leaving group, such as a halogen atom; or

(b) reacting a compound of formula (III)



(III)

wherein R^1, R^3, R^4, m, n, p and q are as defined in claim 1, with a compound of formula R^2-L^2 where R^2 is as defined in claim 1 and L^2 represents a suitable leaving group, such as a halogen atom or a sulfonate such as methanesulfonate; or

(c) reacting a compound of formula (III) as defined above with a compound of formula H-$R^{2'}$=O under reductive conditions, wherein $R^{2'}$ is as defined in claim 1 for R^2 or a group convertible thereto; or

(d) preparing a compound of formula (I) wherein p represents 1 which comprises reduction of a compound of formula (IV)



(IV)

wherein R^1, R^2, R^3, R^4, m, n and q are as defined in claim 1 and L^{3-} represents a suitable counter ion such as a halogen atom; or

(e) deprotecting a compound of formula (I) or converting groups which are protected; and optionally thereafter

(f) interconversion to other compounds of formula (I).